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Abstract 
Influenza A virus (H1N1) 2009, a new swine-origin influenza A virus, has been spread worldwidely and caused 
great public fear. High-throughput transcriptomics and proteomics methods are now being used to identify H1N1 
and H1N1-host interaction. This article reviews recent transcriptomics and proteomics research in H1N1 diagnosis, 
treatment, and H1N1 virus-host interaction, to offer some help for further understanding the infection mechanism 
and controlling H1N1 transmission. 




From March to early April in 2009, a new 
swine-origin influenza A virus (Influenza H1N1 2009) 
emerged in Mexico and the United States (1). This 
virus is unique in comparison to 2008 H1N1 influenza 
viruses with 27.2% difference in the amino acid se-
quence of hemagglutinin (HA) and 18.2% difference 
in that of neuraminidase (NA) (2). These differences 
are likely to be derived through reassortment of two 
or more viruses of swine origin (3). It can be trans-
mitted from pig to human (4), human to human, and 
even from human back to pig (5). By May 11, 2009, 
the virus has spread worldwidely to 30 countries 
through human-to-human transmission, causing the 
World Health Organization (WHO) to raise its pan-
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demic alert to level 5 of 6 during the first few weeks 
of surveillance (6). On June 11, 2009, the WHO 
raised the alert level to phase 6 and declared an H1N1 
pandemic. So far, vaccination is still considered to be 
the best way to control infection. As reviewed by Ba-
ras et al (7), there are vaccinations preventing H1N1, 
H3N2 and B [Fluarix (against HA) and FluLaval 
(against HA)] and H5N1 [Prepandrix (against HA and 
NA)]. On September 8, 2009, China was reported to 
be the first country to use vaccine to control H1N1 
2009 (http://www.tfol.com/10026/12696/12697/2009/ 
9/8/10803926.shtml). However, at the same time, 
broader transmission of H1N1 was reported in China. 
Due to the high mutation rates of virus, the recurring 
emergence of influenza strains is resistant to available 
antiviral medications, and has the potential for a new 
influenza pandemic. So it is necessary and important 
to systematically surveille H1N1, develop new thera-
peutic approaches that can be rapidly deployed, and 
address the issue of recurring resistance. 
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The development of high-throughput genomics (8, 
9), transcriptomics (3, 10, 11) and proteomics (12, 13) 
techniques has facilitated the investigation of many 
complex issues of H1N1 and H1N1-host interactions. 
Although genomics offered great help to understand 
H1N1 and H1N1-host interaction (8), it is functional 
genome (i.e., RNA and proteins) that carries the func-
tion of genes. For example, messenger RNA expres-
sion microarray technology that allows simultaneous 
measurement of tens of thousands of genes has 
greatly increased our ability to detect subtypes of in-
fluenza A (3, 10). Since viruses employ diverse 
strategies to control host cellular processes at the 
post-transcriptional level, studying the proteome of 
H1N1 or host can help us to better understand this 
virus and control its transmission (12, 13). Here we 
review the progress with transcriptomics and pro-
teomics on H1N1, which may provide a better under-
standing of H1N1 infection and shed new lights on 
further research.  
Transcriptomics Research in H1N1  
Diagnosis 
RT-PCR 
PCR is widely used for the detection of H1N1. Poon 
et al (14) reported conventional and real-time 
RT-PCR protocols, and subsequently developed three 
real-time RT-PCR assays for the detection of pan-
demic H1N1 2009 virus using primers and hydrolysis 
probes targeting the HA and matrix (M) genes (15). 
These rapid, sensitive, and specific methods can de-
tect the virus in a 106 dilution of 4×106 TCID50/mL 
using 5 μL as template, which facilitates the identifi-
cation of new cases of pandemic H1N1 2009 virus, 
ensures optimal management to minimize transmis-
sion to vulnerable individuals, and aids surveillance 




To enable a quick response to a potential outbreak, it  
is desirable to have a fast, accurate, and comprehend- 
sive diagnostic method capable of simultaneously  
typing and subtyping influenza viruses. Currently, the  
diagnostic methods available for identifying influenza  
viruses include viral culture, direct fluorescent anti- 
body testing, rapid point-of-care immunoassays,  
RT-PCR, sequencing, and multiplex RT-PCR. Al- 
though viral culture is the “gold standard” for typing  
and subtyping of influenza viruses, it usually takes  
three to seven days to culture the virus (16). Both  
rapid point-of-care immunoassays (17) and real-time  
RT-PCR (15) can provide results within 30 min to 1 h,  
but they do not provide subtype information. Recently,  
different types of microarrays in combination with  
multiplex amplification have been reported for the  
typing and subtyping of influenza viruses (3, 18, 19).  
A recent study showed that a microarray with 46 short  
virus-specific oligonucleotides can be utilized to de- 
tect influenza A virus of 5 subtypes, including H1N1,  
H1N2, H3N2, H5N1 and H9N2 (3). The assay cor- 
rectly and specifically detected and subtyped 11 dif- 
ferent influenza A viruses isolated from human, avian,  
and swine species belonging to the 5 subtypes. When  
tested with 225 clinical samples, 20 were detected to  
be positive using the microarray-based assay, whereas  
only 10 were found positive by the conventional cul- 
ture method. The entire analysis was completed  
within 7 h. A more high-throughput microarray re- 
ported by Huang et al (18) could accurately type and  
subtype 15 different influenza virus isolates, including  
two influenza B, five A/H1N1, six A/H3N2, and two  
A/H5N1 isolates with an analytical sensitivity of 102  
to 103 copies of transcripts per reaction for each of the  
genes. The assay showed a clinical sensitivity of 96%  
and a clinical specificity of 100% through a study of  
146 human clinical specimens.  
A carbohydrate microarray, based on the neogly-
colipid technology, was developed and used for ana-
lyzing the receptor-binding specificity of pandemic 
influenza A 2009 virus (19). A clear distinction was 
found when comparing the receptor-binding repertoire 
of the pandemic H1N1 viruses Cal/09 and Ham/09 
with the seasonal virus Mem/96. The Cal/09 and 
Ham/09 viruses bound not only to the majority of 
α2-6-linked sialyl sequences, but also to a consider-
able range of α2-3-linked sialyl sequences. In contrast, 
Mem/96 bound exclusively to α2-6-linked sialyl se-
quences, even at a high virus concentration, not to the 
α2-3-linked sialyl sequences (19).  
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Infection mechanism 
Mammalian cells have developed complex systems to 
detect and eliminate viral pathogens, while viruses 
have evolved mechanisms to co-opt host processes 
and suppress host defenses. During the course of a 
viral infection, viral proteins interact with an array of 
host proteins. Shapira et al (11) combined genomics 
and transcripteomics to study the physical and regu-
latory map of host-influenza interactions, and pre-
sented the potential roles for some unanticipated host 
and viral proteins in viral infection and the host re-
sponse, including a network of RNA-binding proteins, 
components of WNT signaling, and viral polymerase 
subunits. Karlas et al (20) carried a genome-wide 
RNA interference (RNAi) screen and discovered 287 
human host cell genes influencing influenza A virus 
replication. For example, SON DNA binding protein 
was found to be important for normal trafficking of 
influenza virions to late endosomes early in infection. 
This genome-wide RNAi screen identified many hu-
man host factors crucial for influenza virus replication, 
and offered some help for the dissection of virus-host 
interactions and the identification of drug targets for a 
broad range of influenza viruses.  
Treatment  
RNAi is a powerful tool to silence gene expression. 
Small interfering RNA (siRNA)-induced RNA deg-
radation has been recently used as an antivirus agent 
to inhibit specific virus replication (3, 21-23).  
The siRNA targeting influenza M2 gene (siM2) 
reported by Sui et al (22) potently inhibits viral repli-
cation, including H1N1 virus and highly pathogenic 
avian influenza virus H5N1. Similarly, Zhou et al (23) 
used siRNA technology to interrupt the expression of 
five target sequences (M-48, M-754, M-949, NP-749 
and NP-1383), and found that siRNA treatment tar-
geting conserved regions of influenza virus matrix 
(M2) and nucleocapsid protein (NP) genes could spe-
cifically inhibit influenza A virus replication in 
MDCK cells. The delivery of pS-M48 and 
pS-NP1383 significantly reduced lung virus titers in 
the infected mice, and partially protected the mice 
from lethal influenza virus challenge. Moreover, the 
treatment of pS-M48 and pS-NP1383 suppressed the 
replication of different subtypes of influenza A vi-
ruses, including a highly pathogenic avian isolate 
strain of H5N1.  
Zhou et al (21) created transgenic tobacco plants 
that produce siRNAs targeting the mRNA of the 
non-structural protein NS1 of H1N1. They found that 
agroinfiltration of transgenic tobacco with an Agro-
bacterium strain harboring a 5mNS1-expressing bi-
nary vector causes a reduction of 5mNS1 transcripts 
in the siRNA-accumulating transgenic plants. Fur-
thermore, H1N1 infection of siRNA-transfected 
mammalian cells notably suppressed viral replication. 
These results demonstrate that plant-derived siRNAs 
can inhibit viral propagation through RNAi and could 
potentially be applied in the control of viral-borne 
diseases. 
An siRNA-targeting host protein, promyelocytic 
leukemia protein (PML), was studied by Li et al (24). 
They concluded that the antiviral effect of PML on 
influenza A viruses is viral subtype/strain specific 
according to their findings: (1) The depletion of 
pan-PML by siRNA rendered A549 cells more sus-
ceptible to influenza A virus strains PR8 (H1N1) and 
ST364 (H3N2), but not to strains ST1233 (H1N1), 
Qa199 (H9N2) and Ph2246 (H9N2); (2) Overexpres-
sion of PML-VI in MDCK cells conferred potent re-
sistance to PR8 (H1N1) infection, while maintaining 
their sensitivity to ST1233 (H1N1), ST364 (H3N2), 
Qa199 (H9N2) and Ph2246 (H9N2).  
Prediction of prognosis 
Early identification of the mutation of H1N1 gene and 
prediction of the treatment are very important. Osel-
tamivir-resistant influenza A (H1N1) viruses with 
neuraminidase gene H274Y amino acid substitution 
were proven to be transmitted and retain significant 
pathogenicity and lethality in high-risk patients (25). 
Proteomics in H1N1 
As reviewed above, transcription research is very 
useful in H1N1 diagnosis and treatment. However, it 
is proteins that are ultimately responsible for the func-
tion of cells. During infection, the influenza virus 
modifies the host cell proteome by triggering host 
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anti-viral responses, hijacking host processes, and 
inhibiting host mRNA processing. Studying proteins 
using the technology based on mass spectrometry 
(MS) should provide additional information for H1N1 
research (13, 15, 26-28). 
Diagnosis 
Although the diagnosis of H1N1 based on RNA is 
commonly used, there are still two proteomic reports 
based on the high-throughput capacity and high sensi-
tivity of proteomics technology. Morrissey and Dow-
nard (13) used gel electrophoresis and MS to identify 
protein-protein interactions and the nature of the in-
teraction interface with high-sample throughput and 
sensitivity. Studies on the protein antigens of the in-
fluenza virus have demonstrated that this approach 
can be successfully employed to detect determinants 
within the hemagglutinin antigen of two divergent 
type A forms of the virus in circulation. The determi-
nants are localized to residues 206-224 following 
tryptic digestion of the hemagglutinin antigen. Spe-
cific peptide-antibody complexes formed following 
the treatment of gel-recovered antigen are preserved 
on the MALDI target array. Another study is a host 
peptide research reported by Wahl et al (29). They 
compared peptides eluted from the HLA of naïve and 
infected cells by MS to understand the host-encoded 
peptides presented by class I molecules following 
influenza infection, and identified 20 peptide ligands 
unique to infected cells and 347 peptides with in-
creased presentation following infection. Infection 
with different influenza strains demonstrated that 
proteome changes are predominantly strain-specific, 
with few individual cellular interactions observed in 
multiple viral strains.  
Infection mechanism  
Quantitative proteome-wide profiling of virus infec-
tion can provide insights into complexity and dynam-
ics of virus-host cell interactions and may accelerate 
antiviral research and support optimization of vaccine 
manufacturing processes. Vester et al (27) used 2-D 
differential in-gel electrophoresis (DIGE) and 
nanoHPLC-nanoESI-MS/MS analysis to qualitatively 
and quantitatively determine the dynamic cellular 
proteome responses. Proteins from a cell line used for 
vaccine production (MDCK) and a human lung car-
cinoma cell line (A549) were separated by 2-D DIGE, 
and 16 quantitatively altered protein spots were iden-
tified in both cell lines. Most significant changes were 
found for keratins, major components of the cy-
toskeleton system, and for Mx proteins, inter-
feron-induced key components of the host cell de-
fense. Most likely, these proteins are required for 
supporting functions during influenza viral life cycle 
or host cell stress response.  
Due to the complexity of proteins in cells and tis-
sues, it is difficult to identify proteins with low abun-
dance. Therefore, some researches focused on sub-
cellular proteome (30). Ohman et al (30) used cytoso-
lic and mitochondrial proteomics to reveal the host 
response to influenza A infection at the protein level 
in human macrophages. Through 2-DE for protein 
separation and MS for protein identification, several 
heat shock proteins and fragments of cytoskeletal 
proteins were detected to be up-regulated in cytosolic 
proteomes during influenza A virus infection. In mi-
tochondrial proteomes, simultaneously with the ex-
pression of viral proteins, the levels of intact actin and 
tubulin were highly up-regulated. This was followed 
by the translocation of the components of antiviral 
RNA recognition machinery, including RIG-I (retinoic 
acid-inducible protein I), TRADD (TNFR1-associated 
death domain protein), TRIM25 (tripartite motif pro-
tein 25), and IKKepsilon (inducible IkappaB kinase), 
onto the mitochondria. Cytochalasin D, a potent in-
hibitor of actin polymerization, inhibited influenza A 
virus-induced expression of IFN-beta, IL-29, and 
TNF-alpha, suggesting that intact actin cytoskeleton 
structure is crucial for proper activation of antiviral 
response. At late phases of infection, mitochondrial 
fragmentation of actin was observed, indicating that 
actin fragments are involved in disruption of mito-
chondrial membranes during apoptosis of vi-
rus-infected cells. These results showed that actin and 
RIG-I/MAVS signaling components translocate to 
mitochondria upon influenza A virus infection of hu-
man primary macrophages (30). 
Furthermore, recent advances in biotechnologies 
allow the detection of a complete cell proteome. 
Many differentially expressed proteins were detected. 
It is usually difficult to select proteins for further re-
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search and interpret them in the biological context. A 
protein-protein interaction map might be useful and 
has been used for virus-host research (28, 31). 
Conclusion 
H1N1 continues to spread globally. The great trans-
missions occurred in 2009 have caused great social 
fear and economic losses. It is important to increase 
and coordinate preventive activities at a global level 
to control virus transmission. Fortunately, the vac-
cines for preventing H1N1 2009 were reported in 
August and September 2009. However, it should be 
noted that, this vaccine is not suit for children and 
people who are allergic to eggs. Understanding the 
molecular mechanisms of virulence and pathogenesis 
is critical for developing new antiviral therapies. This 
article has reviewed how global transcriptomic and 
proteomic studies have been used to diagnose and 
treat H1N1 as well as study the infection mechanism. 
Due to its high-throughput capacity, RNA microarray 
may be more suitable for rapid screening and control-
ling the transmission of H1N1 in the future. siRNA 
has been widely used for functional research of genes 
and might bring new methods to control H1N1 trans-
mission. Proteomics has been used for H1N1-host 
interaction research, and might offer new theories to 
the understanding of H1N1. Discovery-based proteo-
mic approaches can aid in identifying the host re-
sponse pathways associated with immunopathology 
and better understanding of how global host responses 
are regulated during viral infection, which is critical 
for the development of novel antiviral treatments. The 
strength of transcriptomics and proteomics-based ap-
proaches lies in their ability to characterize the global 
effects of infection and to serve as a discovery-based 
tool to identify new host response components and 
pathways (8) involved in H1N1 infection for further 
study, which may ultimately lead to novel targets of 
therapeutic intervention. 
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